Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN) : vimarsana.com

Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

Travere Therapeutics, Inc.: Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI (sparsentan) for the Treatment of IgA Nephropathy (IgAN)

finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Related Keywords

Iceland , Japan , Liechtenstein , Norway , Stefan Klotter , Eric Dube , Drug Administration , European Union , Travere Therapeutics Inc , Exchange Commission , Nasdaq , Committee For Medicinal Products Human Use , European Commission , European Medicines Agency , New Drug Application , Medicinal Products , Human Use , About Travere , Travere Therapeutics , Important Safety , Endothelin Receptor Antagonists , Upper Limit , Fetal Toxicity , Kidney Injury , Angiotensin System , Acid Reducing Agents , Steroidal Anti Inflammatory Agents , Including Selective , Increasing Serum Potassium , Reproductive Potential , Full Prescribing Information , Private Securities Litigation Reform Act , Lassen Sie ,